Italy-based P&R Group has signed an agreement to acquire 100% of the Italian pharmaceutical chemical manufacturer Infa Group through the P&R subsidiary Olon SpA.

Olon is one of the largest European developers and manufacturers, supplying APIs for the pharmaceutical industry worldwide both, for generic as well as for contract manufacturing. Olon owns 5 manufacturing sites in northern Italy—Rodano, Settimo Torinese, Garbagnate Milanese, Mulazzano and Dorno—with more than 800 employees while Infa Group, with more than 400 employees, has 2 manufacturing sites in Italy at Labochim and Sifavitor, and 1 in Spain in Derivados Químicos.

The acquisition will broaden and diversify Olon’s portfolio by doubling it up to more than 200 generic products and will strengthen its presence as a contract development and manufacturing organization (CDMO).

“The acquisition of Infa will provide an established custom synthesis presence with customers worldwide and will strengthen our generic position by adding a large amount of products positioning Olon as one of the largest players in Europe,” said Paolo Tubertini, chief executive officer, Olon.

“Infa will be complementary to Olon in the generic field and add new technologies and a broad base capabilities and expertise in the field of contract manufacturing for the development of new intermediates and API,” said Luca Mantovani, chief executive officer, Infa Group.

The merger of Olon and Infa will expand Olon’s product portfolio, which includes, among others, fermented and semi-synthetic API, HPAPIs and cytotoxic compounds, controlled substances, retinoids, antivirals, biologics, recombinant peptides.

Olon and Infa will have available about 130 Active U.S. Drug Master Files (DMFs) and more than 50 EU Certificates of Suitability (COS) or Compliance with the European Pharmacopoeia (CEP) and will rely on 8 manufacturing facilities self-identified under GDUFA.

The acquisition will also strengthen its services to CDMO customers from the early clinical phases up to the commercial manufacturing.